Skip to content Skip to sidebar Skip to footer


Tackling lung cancer in Africa and the Middle East (By Esra Erkomay)

By Esra Erkomay – Oncology Lead, Middle East and Africa, AstraZeneca ( Lung cancer, once rare, is now the highest cause of mortality of cancer worldwide. Responsible for more fatalities than breast, colon, and prostate cancers combined. [1]  It claims a life every 18 seconds. In recent years, wealthier countries have recently experienced a significant…

Read More

Big Pharma Embracing Artificial Intelligence in Drug Development

Big pharmaceutical companies are embracing the wave of artificial intelligence (AI) in drug development. Several companies, including AstraZeneca, Roche, Takeda, and GSK, have highlighted their efforts in utilizing AI across various stages of drug development, from research and development to manufacturing and commercialization. Consulting firm McKinsey & Company previously reported a significant increase in partnerships…

Read More

AstraZeneca, Roche, Takeda, GSK tout AI tools during half-year earnings reports – Endpoints News

Big Phar­ma com­pa­nies are catch­ing the ar­ti­fi­cial in­tel­li­gence wave, ev­i­denced by a num­ber of drug­mak­ers’ com­ments in their half-year earn­ings re­ports this week. A hand­ful of com­pa­nies high­light­ed their AI ef­forts across drug de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion, in­clud­ing As­traZeneca, Roche, Take­da and GSK so far. Con­sult­ing firm McK­in­sey & Com­pa­ny re­port­ed a “rapid rise” in…

Read More

Roche's star eye drug Vabysmo crosses blockbuster threshold as rival stalls at FDA

To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” | To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” Approved by the FDA in January 2022, Vabysmo already crossed the one-billion-dollar sales mark in the first…

Read More

Qureight announces multi-year strategic research collaboration with AstraZeneca

Less than a year after announcing the world’s first digital biomarker for lung fibrosis, Qureight has announced a multi-year strategic research collaboration with AstraZeneca. The agreement with the biopharmaceutical giant will allow AstraZeneca to use Qureight’s proprietary platform and AI technology to conduct research across a range of complex lung diseases, leveraging imaging data analytics…

Read More